Physician profile
David Michael Blackwell
NPI 1104903111
$3,520.08
in general payments reported to CMS, 2019-2025
28 companies · $96.33 in 2025
The $96.33 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,680 · 2020: $1,162 · 2021: $431 · 2022: $121 · 2023: $29.85 · 2025: $96.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $126.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $504.25 | 2019-2021 | |
| Allergan, INC. | $475.44 | 2019-2020 | |
| Novo Nordisk INC | $445.93 | 2019-2021 | |
| Lilly USA, LLC | $303.07 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $264.86 | 2019-2021 | |
| Pfizer INC. | $243.47 | 2019-2021 | |
| Abbvie INC. | $216.74 | 2019-2023 | Qulipta |
| Antares Pharma, INC. | $139.17 | 2019-2020 | |
| Glaxosmithkline, LLC. | $119.69 | 2019-2023 | Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $115.30 | 2019-2022 | |
| Inspire Medical Systems, INC. | $96.33 | 2025 | Inspire |
| Amgen INC. | $89.77 | 2019-2022 | |
| Amarin Pharma, INC. | $84.01 | 2019-2021 | |
| Gilead Sciences, INC. | $71.60 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.01 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Napo Pharmaceuticals INC | $53.35 | 2019-2021 | |
| Shire North American Group INC | $45.74 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $31.66 | 2020-2022 | |
| Adlon Therapeutics L.P. | $26.17 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.45 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.84 | 2021 | |
| Emd Serono, INC. | $15.17 | 2019 | |
| Biogen, INC. | $14.99 | 2020 | |
| Merck Sharp & Dohme LLC | $14.12 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.80 | 2019 | |
| Astellas Pharma US INC | $12.78 | 2020 | |
| Viiv Healthcare Company | $12.16 | 2022 | |
| Jazz Pharmaceuticals INC. | $11.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Blackwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.